Statin use and other factors associated with mortality after major lower extremity amputation

Journal of Vascular Surgery

Volumn 66, Issue 1, 2017, Pages 216-225

  DeCarlo, Charles ^a   Scher, Larry ^b   Shariff, Saadat ^b   Phair, John ^b   Lipsitz, Evan ^b   Garg, Karan ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN;

ABOVE KNEE AMPUTATION; ADULT; AGED; BELOW KNEE AMPUTATION; BODY MASS; CAUCASIAN; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DRUG USE; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY RATE; OVERALL SURVIVAL; PATIENT HISTORY OF CORONARY ARTERY BYPASS GRAFT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION; SURGICAL MORTALITY; TREATMENT INDICATION; ADVERSE EFFECTS; AMPUTATION; CLINICAL PRACTICE; COMORBIDITY; FACTUAL DATABASE; KAPLAN MEIER METHOD; LOWER LIMB; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEW YORK; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; PRACTICE GAP; PROPORTIONAL HAZARDS MODEL; PROTECTION; PROTOCOL COMPLIANCE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMPUTATION; COMORBIDITY; DATABASES, FACTUAL; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LOWER EXTREMITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW YORK CITY; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROFESSIONAL PRACTICE GAPS; PROPORTIONAL HAZARDS MODELS; PROTECTIVE FACTORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85017524185     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2017.01.048     Document Type: Conference Paper

References (24)

1. Goodney, P.P., Tarulli, M., Faerber, A.E., Schanzer, A., Zwolak, R.M., Fifteen-year trends in lower limb amputation, revascularization, and preventive measures among medicare patients. JAMA Surg 150 (2015), 84–86.
2. Karam, J., Shepard, A., Rubinfeld, I., Predictors of operative mortality following major lower extremity amputations using the National Surgical Quality Improvement Program public use data. J Vasc Surg 58 (2013), 1276–1282.
3. Jones, W.S., Patel, M.R., Dai, D., Vemulapalli, S., Subherwal, S., Stafford, J., et al. High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease. Am Heart J 165 (2013), 809–815.
4. Fortington, L.V., Geertzen, J.H., van Netten, J.J., Postema, K., Rommers, G.M., Dijkstra, P.U., Short and long term mortality rates after a lower limb amputation. Eur J Vasc Endovasc Surg 46 (2013), 124–131.
5. Feinglass, J., Pearce, W.H., Martin, G.J., Gibbs, J., Cowper, D., Sorensen, M., et al. Postoperative and late survival outcomes after major amputation: findings from the Department of Veterans Affairs National Surgical Quality Improvement Program. Surgery 130 (2001), 21–29.
6. Nelson, M.T., Greenblatt, D.Y., Soma, G., Rajimanickam, V., Greenberg, C.C., Kent, K.C., Preoperative factors predict mortality after major lower-extremity amputation. Surgery 152 (2012), 685–696.
7. Davenport, D.L., Ritchie, J.D., Xenos, E.S., Incidence and risk factors for 30-day postdischarge mortality in patients with vascular disease undergoing major lower extremity amputation. Ann Vasc Surg 26 (2012), 219–224.
8. Amarenco, P., Bogousslavsky, J., Callahan, A. 3rd, Goldstein, L.B., Hennerici, M., Rudolph, A.E., Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006), 549–559.
9. Pedersen, T.R., Faergeman, O., Kastelein, J.J., Olsson, A.G., Tikkanen, M.J., Holme, I., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005), 2437–2445.
10. Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 (2006), 1155–1163.
11. Suckow, B.D., Kraiss, L.W., Schanzer, A., Stone, D.H., Kalish, J., DeMartino, R.R., et al., Vascular Study Group of New England. Statin therapy after infrainguinal bypass surgery for critical limb ischemia is associated with improved 5-year survival. J Vasc Surg 61 (2015), 126–133.
12. Sohn, M.W., Meadows, J.L., Oh, E.H., Budiman-Mak, E., Lee, T.A., Stone, N.J., et al. Statin use and lower extremity amputation risk in nonelderly diabetic patients. J Vasc Surg 58 (2013), 1578–1585.
13. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Merz, C.N., Blum, C.B., Eckel, R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
14. Sandnes, D.K., Sobel, M., Flum, D.R., Survival after lower-extremity amputation. J Am Coll Surg 199 (2004), 394–402.
15. Subramaniam, B., Pomposelli, F., Talmor, D., Park, K.W., Perioperative and long-term morbidity and mortality after above-knee and below-knee amputations in diabetics and nondiabetics. Anesth Analg 100 (2005), 1241–1247.
16. Jones, R.N., Marshall, W.P., Does the proximity of an amputation, length of time between foot ulcer development and amputation, or glycemic control at the time of amputation affect the mortality rate of people with diabetes who undergo an amputation?. Adv Skin Wound Care 21 (2008), 118–123.
17. Aulivola, B., Hile, C.N., Hamdan, A.D., Sheahan, M.G., Veraldi, J.R., Skillman, J.J., et al. Major lower extremity amputation: outcome of a modern series. Arch Surg 139 (2004), 395–399.
18. Engelhardt, M., Boos, J., Bruijnen, H., Wohlgemuth, W., Willy, C., Tannheimer, M., et al. Critical limb ischaemia: initial treatment and predictors of amputation-free survival. Eur J Vasc Endovasc Surg 43 (2012), 55–61.
19. Cruz, C.P., Eidt, J.F., Capps, C., Kirtley, L., Moursi, M.M., Major lower extremity amputations at a Veterans Affairs hospital. Am J Surg 186 (2003), 449–454.
20. Taylor, S.M., Kalbaugh, C.A., Blackhurst, D.W., Hamontree, S.E., Cull, D.L., Messich, H.S., et al. Preoperative clinical factors predict postoperative functional outcomes after major lower limb amputation: an analysis of 553 consecutive patients. J Vasc Surg 42 (2005), 227–234.
21. Taylor, F., Huffman, M.D., Macedo, A.F., Moore, T.H., Burke, M., Davey Smith, G., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2013, CD004816.
22. Bradley, L., Kirker, S.G., Secondary prevention of arteriosclerosis in lower limb vascular amputees: a missed opportunity. Eur J Vasc Endovasc Surg 32 (2006), 491–493.
23. McGrogan, D., Mark, D., Lee, B., O'Donnell, M.E., Implementation of best medical therapy for cardiovascular risk factors in vascular surgery patients treated in a tertiary referral regional unit. Int J Clin Pract 68 (2014), 1100–1109.
24. Ovbiagele, B., Saver, J.L., Fredieu, A., Suzuki, S., Selco, S., Rajajee, V., et al. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke 35 (2004), 2879–2883.